APA (7th ed.) Citation

Macaya, I., Roman, M., Welch, C., Entrialgo-Cadierno, R., Salmon, M., Santos, A., . . . Vicent, S. (2023, October). Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer. Nature Communications.

Chicago Style (17th ed.) Citation

Macaya, Irati, et al. "Signature-driven Repurposing of Midostaurin for Combination with MEK1/2 and KRASG12C Inhibitors in Lung Cancer." Nature Communications Oct. 2023.

MLA (9th ed.) Citation

Macaya, Irati, et al. "Signature-driven Repurposing of Midostaurin for Combination with MEK1/2 and KRASG12C Inhibitors in Lung Cancer." Nature Communications, Oct. 2023.